Wall Street

Record-Setting Biotech Plunges 25% After Axing Lead Program

Published by
The Street

By Maxx Chatsko The fastest IPO in biotech history is now pumping the brakes. Drug development is time-consuming, expensive, and full of failure. It requires many years and hundreds of millions of dollars (or more) to bring a new drug to market. Most never get to have a launch party. From 2011 to 2020, only 7.9% of drug candidates that began a phase 1 clinical trial earned approval from the U.S. Food and Drug Administration (FDA). Centessa Pharmaceuticals (CNTA) – Get Centessa Pharmaceuticals PLC ADR Report was founded to attack the inefficiency of drug development head on. The business launch…

Read More

Share this Story
Load More Related Articles
Load More In Wall Street